Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
33.74
+1.13 (3.47%)
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with neurological disorders
The company is dedicated to addressing unmet medical needs in this space, particularly in the areas of rare and complex conditions. By leveraging proprietary research and development capabilities, Harmony Biosciences aims to bring forth therapies that improve the quality of life for patients, while also advancing scientific understanding of neurological diseases. Their portfolio includes products targeting specific disorders, reflecting a commitment to enhancing patient outcomes through personalized and effective treatments.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQHRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 2024 net revenues of $714.7 million, ending the year with $576 million in cash, cash equivalents and investments on the balance sheet. The company has guided 2025 WAKIX® net revenues to $820 - $860 million, targeting a $1B+ opportunity with WAKIX in narcolepsy alone.
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony’s 2025 net revenue guidance of $820-$860 million remains unchanged.
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 25, 2025, at 8:30 a.m. ET to discuss the results.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will be highlighting its catalysts for 2025 and other key milestones during its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET.
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
